Myeloma : nature.com subject feeds
Correction to: The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signaling
Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
Real-world renal function among patients with multiple myeloma in the United States
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
The mutagenic impact of melphalan in multiple myeloma
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
BMI1 regulates multiple myeloma-associated macrophage’s pro-myeloma functions
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model
Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma
Co-evolution of tumor and immune cells during progression of multiple myeloma
Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
Chromosome 1q21 abnormalities in multiple myeloma
Sensitive multiple myeloma disease monitoring by mass spectrometry
CAR T-cell therapy in multiple myeloma: more room for improvement
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft
Myeloma-bone marrow adipocyte axis in tumour survival and treatment response
Genetically determined telomere length and multiple myeloma risk and outcome
Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
Feed Fetched by RSS Dog.